Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
Proceeds expected to support Exicure’s continued advancement of preclinical candidates including its SCN9A product candidate, a non-opioid pain analgesicThe private placement is being led by a subsidiary of CBI Co., Ltd. (“CBI”), a member of a leading investment group in South Korea focusing on science-based compani...
Source: pharmiweb.com